Anna Azvolinsky, PhD

A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the treatment of CRPC.

Targeted Oncology spoke about progress in the treatment of HER2-positive breast cancer with breast cancer expert, Sunil Verma, MD, MSEd, FRCPC.

The first combination therapy for advanced melanoma received approval from the Food and Drug Administration (FDA) January 2014.

Melanoma experts and researchers have gained ground in the development of novel and effective immunotherapies as well as targeted agents for those patients with metastatic melanoma who harbor specific tumor mutations.

Many important issues will be addressed in the presentations at the 36th San Antonio Breast Cancer Symposium (SABCS), held annually in San Antonio, Texas, this year December 10-14.

Many important issues will be addressed in the presentations at the 36th San Antonio Breast Cancer Symposium (SABCS), held annually in San Antonio, Texas, this year December 10-14.

The use of cancer immunotherapies has evolved. The latest immunotherapies are not only effective, but also accessible enough to be administered not just by expert immunologists, but by general oncologists.

Targeted Oncology spoke with Shilpa Gupta, MD, from the Moffitt Cancer Center and University of South Florida Morisani College of Medicine, on considerations in choice of therapy for first-line treatment of mRCC.

A Q&A with Jennifer Brown MD, PhD, director of the Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, and assistant professor of Medicine at Harvard Medical School in Boston, MA.

Several oral drugs are in development for both non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL). “There is different activity in different lymphoma types with different oral drugs and antibodies in development,” said Andrew D. Zelenetz, MD, PhD.

A Q&A with Andrew D. Zelenetz, MD, PhD, medical oncologist specializing in lymphoma at Memorial Sloan-Kettering Cancer Center, New York City.

New approaches to treating women with advanced ER+ breast cancer are in development, which includes both hormone therapy and combinations with targeted agents. The continuing goal is to understand disease biology and individualize treatment regimens to increase survival.

With seven targeted therapies approved for metastatic renal cell carcinoma (RCC), researchers and drug developers are now focusing on understanding the best way to sequence these therapies—and on identifying predictive biomarkers of response.

A quick reference chart of the key clinical trials presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting.

Although the use of CTCs as a “liquid biopsy” to detect tumor growth has long been a goal, developing the technology for detecting and analyzing CTCs has been a challenge.

The American Association for Cancer Research is an annual showcase of the latest scientific cancer research, with updates on phase I, often first-in-human clinical trials.

In September 2012, the FDA approved regorafenib as a salvage treatment for metastatic colorectal cancer (mCRC) previously treated with chemotherapy, an antivascular endothelial growth factor therapy, or an anti-EGFR therapy.

A new study suggests that even tumor cells with a common genetic background can display functional heterogeneity.

In advance of the 2013 American Society of Clinical Oncology annual meeting, Targeted Therapy News spoke with this year’s chair of the Scientific Program Committee, Douglas Yee, MD, about key presentations and sessions that attendees can expect.